Generic dealmaking
News | 06 August 2012
For years now, the makers of brand-name and generic prescription drugs have worked together in a collusive practice that adds billions of dollars to the cost of health care. The practice is nicknamed pay-for-delay?the "delay" being the longer stretch ...
Click on the link to read the full article at Chicago Tribune
(This link will open in a new window)
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
